Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

NCT00038662 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00038662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00038662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Lead sponsor
Abbott
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2002
Completion date
Not reported
Enrollment
200
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms